Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DRL-21994
- Development stage
- Unknown
- Lead developer
- Dr. Reddy's Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DRL-21994 is an extended-release formulation of niacin (nicotinic acid) developed by Dr. Reddy's Laboratories for the treatment of hyperlipidaemia and hypertriglyceridaemia. As a niacin-based agent, its mechanism of action involves the activation of the GPR109A (HCA2) receptor and the inhibition of hepatic diacylglycerol acyltransferase-2 (DGAT2). These actions lead to a reduction in triglyceride synthesis and VLDL secretion, while simultaneously raising HDL cholesterol levels. DRL-21994 was investigated in Phase I clinical trials to evaluate its safety, tolerability, and pharmacokinetics, specifically comparing its vasodilatory effects (flushing) against the reference extended-release niacin product, Niaspan, in healthy adult subjects.
- Other names
- nicotinic acid extended-releaseniacin extended-release
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)DGAT2 (Hepatic diacylglycerol acyltransferase 2)
Beyond the preview
Go deeper on DRL-21994.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DRL-21994.